Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
- PMID: 37342686
- PMCID: PMC10278600
- DOI: 10.1364/BOE.488630
Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
Abstract
Solid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented.
Published by Optica Publishing Group under the terms of the Creative Commons Attribution 4.0 License. Further distribution of this work must maintain attribution to the author(s) and the published article’s title, journal citation, and DOI.
Conflict of interest statement
R.C. is a co-author of patents covering Q-Phase (EA 018804 B1, US 8526003 B2, JP 5510676 B2, CN102279555A, EP 2378244 B1, and CZ302491) and a recipient of related royalties from Telight.
Figures







References
LinkOut - more resources
Full Text Sources